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Abstract
Background: Symptom-based surveys suggest that the prevalence of gastrointestinal diseases is lower in China
than in Western countries. The aim of this study was to validate a methodology for the epidemiological
investigation of gastrointestinal symptoms and endoscopic findings in China.
Methods: A randomized, stratified, multi-stage sampling methodology was used to select 18 000 adults aged 18-
80 years from Shanghai, Beijing, Xi'an, Wuhan and Guangzhou. Participants from Shanghai were invited to provide
blood samples and undergo upper gastrointestinal endoscopy. All participants completed Chinese versions of the
Reflux Disease Questionnaire (RDQ) and the modified Rome II questionnaire; 20% were also invited to complete
the 36-item Short Form Health Survey (SF-36) and Epworth Sleepiness Scale (ESS). The psychometric properties
of the questionnaires were evaluated statistically.
Results: The study was completed by 16 091 individuals (response rate: 89.4%), with 3219 (89.4% of those
invited) completing the SF-36 and ESS. All 3153 participants in Shanghai provided blood samples and 1030 (32.7%)
underwent endoscopy. Cronbach's alpha coefficients were 0.89, 0.89, 0.80 and 0.91, respectively, for the RDQ,
modified Rome II questionnaire, ESS and SF-36, supporting internal consistency. Factor analysis supported
construct validity of all questionnaire dimensions except SF-36 psychosocial dimensions.
Conclusion:  This population-based study has great potential to characterize the relationship between
gastrointestinal symptoms and endoscopic findings in China.
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Background
The epidemiology of common gastrointestinal diseases
differs between populations in Asian and in Western
countries, and in Asia particularly, the pattern of these dis-
eases seems to be changing [1]. The prevalence of peptic
ulcer disease has been declining at the same time as the
prevalence of gastroesophageal reflux disease (GERD) and
its complications have been increasing [2]. Gastric cancer
remains a common cancer in Asia, but its prevalence has
also been declining in recent years [1]. These changes may
reflect the experience of Western countries several decades
ago, and comparisons of the epidemiology of gastrointes-
tinal diseases between Western and Asian countries con-
tinue to be of interest.
GERD is a chronic disease in which reflux of gastric con-
tents into the esophagus causes a broad range of trouble-
some symptoms and esophageal complications. The
recent Montreal consensus states that a diagnosis of GERD
can be made based on symptoms alone and, in popula-
tion-based surveys, a defined symptom threshold is
required for making a symptom-based diagnosis [3]. The
historical lack of a single definition of GERD makes com-
parisons between studies difficult. A systematic review of
studies that defined GERD as symptoms of heartburn
and/or acid regurgitation experienced at least once a week
concluded that GERD is relatively uncommon in Asia,
with a prevalence of approximately 5%; this compared
with 10-20% in Western countries [4]. However, the rec-
ommendations of the Montreal consensus [3] have not
yet been applied to epidemiological studies of GERD. Fur-
thermore, the existence of essentially asymptomatic reflux
esophagitis - seen in studies of Asian individuals undergo-
ing upper gastrointestinal endoscopy as part of a routine
health check [5,6] and population-based endoscopic
studies of GERD conducted in Europe [7,8] - means that
population-based endoscopic studies are needed to
understand the epidemiology of GERD in Asia.
Irritable bowel syndrome (IBS) and dyspepsia are both
common gastrointestinal disorders in the West, affecting
10-20% [9] and 20-40% [10] of the population, respec-
tively. They are frequently diagnosed based on symptoms,
and often coexist in the same patient [11]. Data on the
epidemiology of IBS and dyspepsia are limited in Asian
countries, and prevalence estimates vary widely [12,13].
However, the prevalence of IBS appears to be lower in Asia
than in the West [14], with a prevalence of 3.8-6.6% in
China according to Rome II criteria [15-18]. The preva-
lence of dyspepsia in populations from Korea, Taiwan and
China is 11.7-18.4%, according to Rome II criteria
[13,19]. Further studies of IBS, dyspepsia and their rela-
tionship to each other, and to GERD, are needed in Asia.
The variation in prevalence of Helicobacter pylori infection
is one potential explanation for the differences in the epi-
demiology of upper gastrointestinal diseases between
Asian and Western populations and the changing patterns
seen in Asia [2]. H. pylori infection remains more preva-
lent in Asia than in the West [20,21], where infection rates
have declined in recent decades alongside improving soci-
oeconomic conditions and the availability of eradication
therapy [21,22]. Eradication of H. pylori has an important
role in the treatment or prevention of peptic ulcer disease,
dyspepsia and gastric cancer [21,23]. However, the role of
H. pylori in GERD remains controversial [24]; H. pylori
infection has been negatively associated with GERD in
population studies from Asia, but the results of eradica-
tion studies in patients with peptic ulcer disease are incon-
sistent [25,26].
Asian population-based studies, including endoscopic
data and testing for H. pylori, are required to clarify the
complex relationships between symptom-based GERD,
reflux esophagitis, dyspepsia, IBS, peptic ulcer disease and
H. pylori infection. We have previously conducted a pilot
study in Shanghai to validate the methodology for the epi-
demiological study of GERD in China [27]. This article
reports the validation of a refined methodology in the Sys-
tematic Investigation of Gastrointestinal Diseases in
China (SILC) study, which set out to investigate the epide-
miology of upper and lower gastrointestinal diseases in
five regions across China using symptom questionnaires
that have undergone appropriate validation. The study
aimed to collect reliable information on symptom pat-
terns, comorbidities, health-related quality of life and
findings from endoscopy, esophageal biopsy and labora-
tory investigations, including tests for H. pylori infection.
Methods
Setting
This study was conducted in five diverse regions of China,
all of which are major population centres (Figure 1).
Sampling
In total, 18 000 adults aged 18-80 years were randomly
selected from Shanghai, Beijing, Xi'an, Wuhan and
Guangzhou, using a stratified, multi-stage sampling
methodology. Given that urban and rural populations are
widely divergent in terms of environment and socioeco-
nomic status, and because approximately half of the resi-
dents of these centres live in rural areas (Shanghai: 54.2%;
Beijing: 42.5%; Xi'an: 50.4%; Wuhan: 41.4%;
Guangzhou: 55.7% [28-33]), urban and rural populations
were treated as two separate strata and sampled in a ratio
of 1:1 (n = 1800 for each stratum in each region). At the
first sampling stage, one or more districts from the urban
stratum and one or more counties from the rural stratum
were randomly selected from each region. At the second
stage, one or more blocks were randomly selected from
the urban districts, and one or more townships from the
rural counties. At the third stage, one or more residentialBMC Gastroenterology 2009, 9:86 http://www.biomedcentral.com/1471-230X/9/86
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areas were randomly sampled from the urban blocks, and
one or more villages from the rural townships.
All residents of the selected residential areas or villages
were stratified according to their age and sex, and individ-
uals were randomly selected from these strata in propor-
tion to the overall age and sex distribution of the
population in that region, using data from recent govern-
ment population surveys (The Fifth Population Census In
China, 2000, or the 1% sample survey, 2005) [34-39]. Res-
idents who were younger than 18 years, older than 80
years, illiterate, or who had major psychiatric illness or
severe visual, hearing or learning disabilities, were
excluded from the study.
Study design
All selected individuals were asked to complete a general
information questionnaire, and Chinese versions of the
Reflux Disease Questionnaire (RDQ) [40] and modified
Rome II questionnaire (Figure 2) [41]. In addition, a ran-
dom sub-sample of the total sample, 20% in each region,
was asked to complete Chinese versions of the 36-item
Short-Form Health Survey (SF-36) [42] and the Epworth
Sleepiness Scale (ESS) [43] and to undergo a physical
examination that included measurement of weight (kg),
height (cm), and waist and hip circumference (cm). Meas-
urements were made with individuals wearing indoor
clothing without shoes. Weight was measured on an elec-
tronic scale to the nearest 0.1 kg, and height and circum-
ference measurements were recorded to the nearest
centimetre.
All participants from the Shanghai region were invited to
undergo upper gastrointestinal endoscopy with esopha-
geal biopsy. Endoscopic results were classified using the
Los Angeles (LA) classification of reflux esophagitis [44]
and the Prague C and M classification of endoscopically
suspected esophageal metaplasia [45]. Markers of micro-
scopic esophagitis from biopsies were classified using cri-
teria developed by an international panel of expert
pathologists [46]. Individuals in Shanghai were also asked
to provide blood samples for H. pylori antibody serology
using an immunoglobulin G enzyme-linked immuno-
sorbent assay (ELISA) (Biohit, Helsinki, Finland).
Administration
The fieldwork period was from April 2007 to January
2008. Questionnaires were self-administered, with
trained and supervised facilitators available to explain any
questions that respondents found unclear. (Most queries
were about the questionnaire formats, such as the skip
The five study regions in China Figure 1
The five study regions in China.
Beijing
Shanghai
Wuhan
Guangzhou
Xi'an
The survey sampling design Figure 2
The survey sampling design.
Total study population (general information 
questionnaire, Reflux Disease Questionnaire,
modified Rome II questionnaire)
20% sample (with addition of SF-36 questionnaire,
Epworth Sleepiness Scale and physical examination)
Shanghai sample (with addition of blood sampling 
and endoscopy with biopsy)
Beijing
Xi’an
Wuhan
Guangzhou
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rules in the modified Rome II questionnaire.) Participants
completed the questionnaires at home or in local residen-
tial committee offices. Three attempts were made to con-
tact a resident before he or she was considered to be a
non-responder.
To encourage high response rates, local residential com-
mittee staff publicized the survey in the selected residen-
tial areas and villages using leaflets and posters. They also
supported participation by setting up early morning and
weekend sessions in local residential committee offices,
where individuals could come to complete the question-
naires without this interfering with their daily routines. In
addition, a small gift (such as shampoo or washing pow-
der) was offered to reward participation. In the Shanghai
region, the diagnostic benefits of a free blood test and
endoscopy with biopsy were explained, along with the
need to fast overnight. Breakfast was provided for those
who underwent blood tests and/or endoscopy, and partic-
ipants were transported to and from the hospital where
endoscopy was performed. Individuals were subsequently
provided with all test results.
The study was staffed by graduates from the Department
of Health Statistics, Second Military Medical University in
Shanghai, who received training centrally from gastroin-
testinal specialists and epidemiologists in Shanghai. Most
had also taken part in the pilot survey in Shanghai and
were familiar with the survey process. These study staff
provided standardized training for facilitators, who were
local university graduates or social workers at the sampled
sites, before fieldwork commenced. After each question-
naire had been completed, it was checked for complete-
ness and signed by the responsible member of the study
staff before the participant received their gift.
Informed consent was obtained from study participants,
who were free to discontinue their involvement in the
study at any time. The study was approved by the Ethics
Committee of the Second Military Medical University in
Shanghai, China.
Questionnaires
The general information questionnaire collected data on
age, height, weight, sex, marital status, education, income,
occupation, lifestyle, self-reported health status, family
history of gastrointestinal diseases, and medical history
(current and previous medical problems and related treat-
ment). Current smoking was defined as smoking at least
one cigarette daily, and drinking alcohol was classified as
alcohol consumption on four or more occasions per
month. Current occupation was classified as white-collar
worker (including government employees, professionals
and technicians), manufacturing industry worker, agricul-
tural or fisheries worker, and other (including service sec-
tor and students). Participants indicated their health
status, total monthly family income and weekly level of
recreational exercise by selecting an option from appro-
priate categories.
The RDQ is a 12-item, patient-reported questionnaire that
assesses the frequency and severity of upper gastrointesti-
nal symptoms such as heartburn, regurgitation and epi-
gastric pain. In this study, a 1-month recall period was
used. Each item was scored on a 6-point Likert scale
(Table 1). Traditionally, the items are combined into the
dimensions of heartburn (burning behind the breastbone
and pain behind the breastbone), regurgitation (acid taste
in the mouth and movement of materials upwards from
the stomach) and epigastric pain (epigastric pain and epi-
gastric burning) [40]. A GERD dimension can be obtained
by combining the heartburn and regurgitation dimen-
sions, and the epigastric pain dimension is also known as
the dyspepsia dimension. There is strong evidence sup-
porting the validity and reliability of the RDQ as a diag-
nostic tool in primary care [47] and as a measure of
treatment response in clinical trials [48,49]. Previous
investigators found that a Chinese version of the RDQ
tested in 10 hospitals in China was able to identify the
presence of reflux symptoms experienced during the pre-
vious month [50]. The Chinese version of the RDQ used
in the present study underwent extensive linguistic valida-
tion, including forward and backward translation, cogni-
tive debriefing of patients with GERD, and expert input
from gastroenterologists. The pilot study in Shanghai
showed that a version with a 1-week recall period had
credible reliability and construct validity [27]. In the cur-
rent study, an item was added immediately after the RDQ
that asked participants to rate how troublesome they
found the symptoms that they had scored in the RDQ
overall, using a 5-point scale (where the lowest score was
'not at all' and the highest score was 'extremely').
The Rome II questionnaire is designed to assess symptoms
of upper and lower functional gastrointestinal disorders,
including esophageal disorders, gastroduodenal disor-
ders, bowel disorders, functional abdominal pain, biliary
disorders and anorectal disorders, in a 3-month recall
period [41]. The Rome II questionnaire is widely used in
research and clinical practice, and there is evidence sup-
porting its validity across various cultures in Asia and the
West, including a Chinese version in China [51-53]. The
version of the Rome II questionnaire used in this study
was translated into Chinese through a process of forward-
and back-translation and reconciliation, and then tested
for linguistic validity through a process of cognitive
debriefing with literate volunteers. It was also modified by
removal of reflux items covered by the RDQ, to shorten
the survey for participants and minimize repetition and
possible confusion. Individuals answered yes or no toBMC Gastroenterology 2009, 9:86 http://www.biomedcentral.com/1471-230X/9/86
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eight mandatory items, and a further 16 items covering
gastroduodenal, bowel and biliary symptoms were com-
pleted only if relevant.
The SF-36 is a generic questionnaire that is widely used to
assess health status and well-being during the previous 4
weeks. It contains 36 items, clustered into eight dimen-
sions (physical functioning, role-physical, bodily pain,
general health, vitality, social functioning, role-emotional
and mental health), plus one item on health change dur-
ing the previous year [42]. The score for each dimension
is the sum of the scores of each item it contains, trans-
formed to a value on a scale of 0 to 100, with high scores
indicating good health-related quality of life. The reliabil-
ity and validity of the SF-36 are well documented in a
range of language versions, including Chinese [54-56].
The psychometric properties of the Chinese version of the
SF-36 used in this study were assessed during the pilot
study in Shanghai [27]. The questionnaire was found to
have credible reliability and construct validity.
The ESS is an eight-item, self-administered questionnaire
that is widely used to measure daytime sleepiness in
adults [43]. The likelihood of dozing in various everyday
situations is scored on a 4-point Likert scale, where a score
of 3 indicates a high risk of dozing during the daytime and
a score of 0 indicates no risk of dozing. Item scores are
summed to produce a final score in the range 0-24. ESS
scores above 12 suggest problems with excessive sleepi-
ness, scores of 10-12 are borderline, and scores below 10
are considered normal. The reliability of the ESS has been
demonstrated in English in Australia [57] and in Chinese
in Hong Kong [58]. For use in the present study, it was
translated into Chinese through a process of forward- and
back-translation and reconciliation, and then tested for
linguistic validity through a process of cognitive debrief-
ing with literate volunteers.
Data collection and analysis
Coding and double entry of questionnaire responses were
carried out by two independent professional data-entry
staff from the Department of Health Statistics. EpiData
software (EpiData Foundation, Odense, Denmark) [59]
was used to check for consistency between the two sets of
data entries to ensure data quality. SAS 9.1.3 software
(SAS Institute, Cary, NC, USA) was used for the data anal-
yses. The mean value of the completed items was used to
impute missing values where at least 50% of the items in
an RDQ or SF-36 dimension or in the overall ESS had
been completed. When values were missing for more than
50% of items, the dimension score (or questionnaire
score for the ESS) was excluded from the analysis [60-62].
Table 1: Scoring system of the Reflux Disease Questionnaire (RDQ).
Item Frequency
None Less than one day a week One day
a week
2-3 days
a week
4-6 days a week Daily
Burning behind the breastbone 0 1 2 3 4 5
Pain behind the breastbone 0 1 2 3 4 5
Acid taste in the mouth 0 1 2 3 4 5
Unpleasant movement of material upwards 
from the stomach
01 2 3 4 5
Epigastric burning 0 1 2 3 4 5
Epigastric pain 0 1 2 3 4 5
Item Severity
None Very mild Mild Moderate Moderately severe Severe
Burning behind the breastbone 0 1 2 3 4 5
Pain behind the breastbone 0 1 2 3 4 5
Acid taste in the mouth 0 1 2 3 4 5
Unpleasant movement of material upwards 
from the stomach
01 2 3 4 5
Epigastric burning 0 1 2 3 4 5
Epigastric pain 0 1 2 3 4 5BMC Gastroenterology 2009, 9:86 http://www.biomedcentral.com/1471-230X/9/86
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For the modified Rome II questionnaire, imputation was
not performed if an item score was missing.
The internal consistency of survey instruments was evalu-
ated using Cronbach's alpha coefficient to determine the
extent to which items within each questionnaire were
interrelated [63]. Cronbach's alpha coefficients for each
questionnaire were calculated by correlating all individual
item scores with dimension scores and/or the overall
score. An alpha coefficient above 0.70 suggested good
internal consistency. Correlation and/or factor analyses
were used to evaluate the construct validity of the RDQ,
Rome II questionnaire and the SF-36 - in other words,
whether each questionnaire actually measures the phe-
nomena that it theoretically predicts. Factor analysis using
principal component analysis and quartimax rotation was
employed to explore the factor structure of each question-
naire. Factor loadings larger than 0.50 within one dimen-
sion were considered to support the factor construct,
provided that the factor loadings were low across the
other dimensions; cumulative rates were used to show the
contributions of combinations of principal components
[64]. Correlation analysis was used to measure the
strength of association between dimension scores and the
total score for the SF-36 questionnaire, and between item
scores and dimension scores for the RDQ. A correlation
coefficient of more than 0.6 was considered to indicate a
strong correlation, 0.3-0.6 a moderate correlation, and
less than 0.3 a weak correlation [65].
Body mass index (BMI) was calculated from self-reported
height and weight measurements from the general infor-
mation questionnaire and, in the 20% sub-sample, from
measurements taken by study staff as part of the physical
examination. Respondents were categorized on the basis
of BMI as having a low risk of cardiovascular disease and
type 2 diabetes (< 18.5 kg/m2, underweight), an increas-
ing but acceptable risk (18.5-22.9 kg/m2, normal weight),
an increased risk (23.0-27.4 kg/m2, overweight) or a high
risk (≥ 27.5 kg/m2, obese) [66]. Agreement between par-
ticipant-reported height and weight and the measure-
ments made by study staff was assessed using the
intraclass correlation coefficient (ICC).
Disease definitions
Based on the Montreal definition of GERD for popula-
tion-based studies [3], the RDQ was used to define symp-
tom-defined GERD as mild symptoms of heartburn
('burning behind the breastbone' and/or 'pain behind the
breastbone') and/or regurgitation ('acid taste in the
mouth' and/or 'unpleasant movement of materials
upwards from the stomach') occurring on at least 2 days a
week (RDQ item frequency score ≥ 3 for a severity score of
≥ 2), or moderate/severe symptoms of heartburn and/or
regurgitation occurring on at least 1 day a week (RDQ
item frequency score ≥ 2 for a severity score ≥ 3).
As described above, reflux esophagitis was graded using
the LA classification system [44] and endoscopically sus-
pected esophageal metaplasia (suspected Barrett's esopha-
gus) was assessed using the Prague C and M criteria [45].
Hiatal hernia was defined as gastric folds extending at
least 2 cm above the diaphragmatic hiatus during quiet
respiration.
Peptic ulcer disease was defined as a defect in the gastric
or duodenal wall that extended through the muscularis
mucosae into the deeper layers of the wall (submucosa or
the muscularis propria). H. pylori test results were classi-
fied as positive (≥ 38 enzyme immunoassay units [EIU])
or negative (< 38 EIU) [67].
Atrophic gastritis was defined on the basis of the more
severely affected of the serum pepsinogen (PG) I concen-
tration and the PGI/PGII ratio. Results were classified
according to the manufacturer's recommendations for
China. PGI levels < 30 μg/L and/or a PGI/PGII ratio < 3
indicated severe atrophy (achlorhydric or very hypochlo-
rhydric conditions). PGI levels from 30 μg/L to < 50 μg/L
and/or a PGI/PGII ratio from 3 to < 5 indicated moderate
atrophy. PGI levels from 50 μg/L to < 70 μg/L and/or a
PGI/PGII ratio from 5 to < 7 indicated mild atrophy
(hypochlorhydric conditions). Levels above the cut-offs
but in the presence of H. pylori antibodies indicated non-
atrophic H. pylori gastritis.
IBS was defined according to the Rome II criteria as
abdominal discomfort or pain that has at least two of the
following three features: (1) relieved with defecation; (2)
onset associated with a change in frequency of stool; and/
or (3) onset associated with a change in form (appear-
ance) of stool [68]. IBS was described as diarrhoea-pre-
dominant (IBS-D) if patients had one or more of the
following: more than three bowel movements a day, loose
(mushy) or watery stools, and/or urgency (having to rush
to have a bowel movement); and none of the following:
fewer than three bowel movements a week, hard or lumpy
stools, and/or straining during a bowel movement. IBS
was described as constipation-predominant (IBS-C) if
patients had one or more of the following: fewer than
three bowel movements a week, hard or lumpy stools,
and/or straining during a bowel movement; and none of
the following: more than three bowel movements a day,
loose (mushy) or watery stools, and/or urgency (having to
rush to have a bowel movement).
Dyspepsia was defined according to the Rome II criteria as
persistent or recurrent pain or discomfort centred in the
upper abdomen, with no evidence that symptoms are
exclusively relieved by defecation or associated with the
onset of a change in stool frequency or stool form [69].
Dyspepsia was described as ulcer-like if the predominant
(most bothersome) symptom was pain centred in theBMC Gastroenterology 2009, 9:86 http://www.biomedcentral.com/1471-230X/9/86
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upper abdomen. Dyspepsia was described as dysmotility-
like if the predominant symptom was an unpleasant or
troublesome nonpainful sensation (discomfort) centred
in the upper abdomen; this sensation may be character-
ized by or associated with upper abdominal fullness, early
satiety, bloating or nausea.
Results
Response rate
In total, 16 091 individuals completed the questionnaires
within a period of 10 months in 2007 and 2008. The
response rate ranged from 87.6% to 91.4% in the different
regions, and the overall response rate was 89.4% (Table
2). In all five regions, the response rate was lower in men
(78.7-89.9%) than in women (91.5-98.4%), and was gen-
erally lowest in the youngest age group (73.1-85.2% in
18-29 year-olds). Nearly half of the non-responders to the
survey were in the 18-29-year-old age group; the response
rate in this group was lower in men (75.2%) than in
women (86.5%) overall and in all regions (data not
shown). Thirteen participants were excluded from the
analysis because of logical errors or insufficient comple-
tion of questionnaires, leaving a total of 16 078 individu-
als suitable for inclusion in the analysis.
In the 20% sub-sample, 3219 individuals responded,
equating to a response rate of 89.4% overall (82.2-93.9%
in the different regions), and data from 3214 individuals
were suitable for analysis (Table 2). In the Shanghai sam-
ple, all 3153 participants (100%) provided blood sam-
ples, of which 3151 were suitable for inclusion in the
analysis, and 1030 (32.7%) volunteered to undergo
endoscopy with biopsy, of whom 1029 were suitable for
inclusion in the analysis of endoscopic data. Six partici-
pants did not undergo biopsy because they met biopsy
exclusion criteria (e.g. presence of esophageal varices or
angioma), leaving 1022 individuals with biopsy results
suitable for analysis.
Participants
The mean age of the participants was 43 years, and 52%
were women (Table 3). BMI ranged from 11.8 kg/m2 to
41.0 kg/m2, with a mean BMI of 22.6 kg/m2. According to
the BMI ranges appropriate for the population [66],
34.4% of participants were overweight and 8.1% were
obese. When self-reported height and weight data were
compared with measurements taken by study staff in the
20% sub-sample, ICCs of 0.97 and 0.98, respectively,
were obtained, indicating that the self-reported values
were reliable. Most participants were married (78%), did
not smoke (72%) and did not drink alcohol (80%).
Almost all smokers (95.6%) and drinkers (92.8%) were
male. Further socioeconomic characteristics of partici-
pants are summarized in Table 4. The age and sex distri-
bution of the participants was broadly representative of
the distribution of the general population in each region
(Table 5), although individuals in the youngest age
groups were slightly under-represented at each study site.
Several demographic variables differed between those
who did and those who did not volunteer for endoscopy
in the Shanghai region. Greater proportions of partici-
pants who underwent endoscopy lived in a rural environ-
ment (63.1%, versus 43.8% of those who did not undergo
endoscopy) or had a family history of gastrointestinal dis-
eases (23.7% versus 11.5%), whereas the proportions of
individuals who were in the youngest age range (18-29
years; 5.3% versus 13.9%), who were unmarried (3.8%
Table 2: Numbers of participants (and response rates) for the randomized samples in each region.
Shanghai Beijing Wuhan Xi'an Guangzhou Total
Total sample 3153 (87.6%)a 3171 (88.1%) 3291 (91.4%) 3266 (90.7%) 3210 (89.2%) 16 091 (89.4%)
80% sub-sample 2510 (87.2%)a 2579 (89.5%) 2615 (90.8%) 2622 (91.0%) 2546 (88.4%) 12 872 (89.4%)
• General information questionnaire
￿ RDQ
￿ Modified Rome II questionnaire
20% sub-sample 643 (89.3%)a 592 (82.2%) 676 (93.9%) 644 (89.4%) 664 (92.2%) 3219 (89.4%)
￿ General information questionnaire
￿ RDQ
￿ Modified Rome II questionnaire
￿ SF-36
￿ ESS
￿ Physical examination
ESS, Epworth Sleepiness Scale; GI, gastrointestinal; RDQ, Reflux Disease Questionnaire; SF-36, 36-item Short-Form Health Survey.
aIn Shanghai, all 3153 respondents to the initial survey underwent blood sampling (100% response rate), and 1030 participants (32.7%) accepted the 
invitation to undergo upper gastrointestinal endoscopy with esophageal biopsy, 764 (30.4%) in the 80% sub-sample and 266 (41.4%) in the 20% sub-
sampleBMC Gastroenterology 2009, 9:86 http://www.biomedcentral.com/1471-230X/9/86
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versus 11.9%) or who were college graduates (8.9% versus
14.2%) were lower among the population who under-
went endoscopy than the population that did not (all p ≤
0.001). Sex, BMI, occupation, annual income, smoking
status and alcohol consumption were similar among
those who underwent endoscopy and those who did not.
Reliability
Internal consistency (indicated by Cronbach's alpha coef-
ficient) was above 0.7 for all questionnaires, demonstrat-
ing good reliability. Cronbach's alpha coefficient was 0.89
for the RDQ, 0.89 for the modified Rome II question-
naire, 0.80 for the ESS, and 0.91 for the overall SF-36. For
seven of the eight individual SF-36 dimensions, Cron-
bach's alpha coefficient was above 0.7 (0.75-0.92), but for
social functioning it was 0.51.
Construct validity
The RDQ, modified Rome II and SF-36 all demonstrated
credible construct validity using correlation and/or factor
analyses. For the RDQ, each dimension correlated most
strongly with the items comprising it (Spearman correla-
tion coefficients 0.63-0.87, p  < 0.001; Table 6). Factor
analysis of the RDQ indicated that the 12 items distrib-
uted to four factors that supported the theoretical con-
struct of the RDQ (one representing the regurgitation
dimension, another representing the heartburn dimen-
sion and two representing the dyspepsia dimension). Fac-
tor loadings ranged from 0.67 to 0.88, and the cumulative
rate of the four factors was 80.1%.
Factor analysis of the modified Rome II questionnaire
revealed that the 37 items distributed to seven factors with
Table 3: Demographics and lifestyle characteristics of participants by region.
Variables Shanghai
(n = 3151)
Beijing
(n = 3168)
Wuhan
(n = 3283)
Xi'an
(n = 3266)
Guangzhou
(n = 3210)
Total (n = 16 078)
Age (years) 47.7 ± 14.1 42.7 ± 15.3 41.5 ± 15.4 41.6 ± 15.2 39.0 ± 14.3 42.5 ± 15.2
Weight (kg) 63.0 ± 11.4 65.1 ± 11.4 60.1 ± 10.1 60.8 ± 10.2 57.8 ± 9.9 61.3 ± 10.9
Height (cm) 164.4 ± 8.1 165.8 ± 8.0 164.1 ± 7.6 165.3 ± 7.7 162.4 ± 8.1 164.4 ± 8.0
Body mass index (kg/m2) 23.2 ± 3.3 23.7 ± 3.5 22.3 ± 3.2 22.2 ± 3.2 21.9 ± 3.1 22.6 ± 3.3
Female sex 1749 (55.5) 1682 (53.1) 1719 (52.4) 1647 (50.4) 1593 (49.6) 8390 (52.2)
Urban area 1572 (49.9) 1551 (49.0) 1653 (50.4) 1617 (49.5) 1679 (52.3) 8072 (50.2)
Smoking 926 (29.4) 962 (30.4) 899 (27.4) 912 (27.9) 732 (22.8) 4431 (27.6)
Alcohol use (≥ 4 times per month) 628 (19.9) 780 (24.6) 791 (24.1) 528 (16.2) 535 (16.7) 3262 (20.3)
Family history of gastrointestinal disease 487 (15.5) 98 (3.1) 396 (12.1) 275 (8.4) 171 (5.3) 1427 (8.9)
Married 2693 (85.5) 2421 (76.4) 2597 (79.1) 2583 (79.1) 2288 (71.3) 12 582 (78.3)
Data are mean ± standard deviation or number (%) of participants.
Table 4: Socioeconomic characteristics of participants by region.
Variables Shanghai
(n = 3151)
Beijing
(n = 3168)
Wuhan
(n = 3283)
Xi'an
(n = 3266)
Guangzhou
(n = 3210)
Total (n = 16 078)
Maximum education level
Primary school/uneducated 595 (18.9) 427 (13.5) 914 (27.8) 659 (20.2) 587 (18.3) 3182 (19.8)
Secondary/high school 2162 (68.6) 1884 (59.5) 2056 (62.6) 1920 (58.8) 1908 (59.4) 9930 (61.8)
College graduate 394 (12.5) 857 (27.1) 312 (9.5) 687 (21.0) 714 (22.2) 2964 (18.4)
Current occupationa
White-collar worker 756 (24.0) 666 (21.0) 395 (12.0) 844 (25.8) 897 (27.9) 3558 (22.1)
Manufacturing industry worker 680 (21.6) 299 (9.4) 464 (14.1) 297 (9.1) 739 (23.0) 2479 (15.4)
Agricultural or fisheries worker 729 (23.1) 1343 (42.4) 1083 (33.0) 1355 (41.5) 302 (9.4) 4812 (29.9)
Other 985 (31.3) 858 (27.1) 1333 (40.6) 766 (23.5) 1266 (39.4) 5208 (32.4)
Total family income per monthb
≤ 1999 yuan 1246 (39.5) 1727 (54.5) 2132 (64.9) 2236 (68.5) 1474 (45.9) 8815 (54.8)
2000-4999 yuan 1574 (50.0) 1240 (39.1) 989 (30.1) 899 (27.5) 1261 (39.3) 5963 (37.1)
≥ 5000 yuan 324 (10.3) 192 (6.1) 160 (4.9) 130 (4.0) 453 (14.1) 1259 (7.8)
Data are number (%) of participants.
aWhite-collar workers included government employees, technicians and professionals, and other workers included service sector employees and 
students.
bAverage yearly income in China in 2007: 24 932 yuan (~$3300) [76].
NOTE: numbers may not add up exactly to 100% for each socioeconomic category where individual participants have refused to answer specific 
questions on the general information questionnaire.B
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Table 5: Age and sex distribution in the general population and in study participants in each region.
Shanghai (%) Beijing (%) Wuhan (%) Xi'an (%) Guangzhou (%)
Populationa
(n = 13.5 m)
Participants
(n = 3151)
Populationb
(n = 11.8 m)
Participants
(n = 3168)
Populationb
(n = 7.8 m)
Participants
(n = 3283)
Populationa
(n = 7.3 m)
Participants
(n = 3266)
Populationb
(n = 7.3 m)
Participants
(n = 3210)
Female 50.6 55.5 50.0 53.1 49.7 52.4 50.0 50.4 45.4 49.6
Urban 54.2 49.9 57.5 49.0 58.6 50.4 50.4 49.5 55.7 52.3
Age (years)
18-29 13.3 11.1 25.6 23.9 31.1 26.5 27.8 24.8 31.9 27.8
30-39 18.8 15.8 21.5 21.1 19.6 22.8 25.7 25.2 28.5 29.2
40-49 30.2 33.8 22.0 23.1 20.3 20.8 19.9 21.2 17.8 19.9
50-59 16.4 18.9 15.1 16.0 15.5 15.4 12.9 13.8 11.5 12.7
60-69 12.4 12.1 9.3 9.8 8.0 8.5 8.8 9.5 6.3 7.0
70-80 9.1 8.3 6.5 6.1 5.5 6.1 5.0 5.4 4.0 3.5
aData from the fifth population census in China (2000) [35,39].
bData from the government 1% sample survey (2005) [36-38].
m, million.BMC Gastroenterology 2009, 9:86 http://www.biomedcentral.com/1471-230X/9/86
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factor loadings that ranged from 0.57 to 0.94. The cumu-
lative rate of the seven factors was 78.9%. These factors,
representing dimensions of functional dyspepsia, IBS, an
IBS subtype, biliary disorders, functional vomiting, aer-
ophagia and an integrated dimension, provide empirical
support for the validity of the Rome II classification sys-
tem in China.
For the SF-36, all dimensions correlated most strongly
with the items comprising it, except the physical function-
ing dimension. Spearman correlation coefficients for the
association between an item score and its dimension score
were greater than 0.6 (range 0.61-0.99) for all items
except seven out of the ten physical functioning items
(range 0.25-0.50). In factor analysis of the SF-36, the 36
items distributed to eight factors that generally supported
the theoretical construct of the questionnaire (cumulative
rate of 65.5%). Most items were distributed as expected
from the theoretical construct (factor loadings 0.48-0.86),
except for all mental health and vitality items, which were
distributed to two factors (factor loadings 0.61-0.78); the
social functioning items, which did not resolve into a dis-
tinct factor, but instead were distributed most strongly to
role-emotional and mental health/vitality factors (factor
loadings 0.45 and 0.43, respectively); and one general
health item, which was also not clearly distributed to the
expected factor.
Discussion
The purpose of this study was to evaluate the validity of
the methodology used to conduct the largest multicentre
population-based survey of gastrointestinal symptoms in
China to date, and the first to include upper gastrointesti-
nal endoscopy with biopsy. The methodology was based
on that applied in a pilot study in Shanghai [27], which
verified the feasibility of conducting this larger and more
extensive multicentre study.
High response rates were achieved to the simple, validated
questionnaires used and, although the youngest age group
was slightly under-represented, the survey sample was
broadly representative of the general population in the
survey regions. However, response rates are likely to have
been low among migrant workers, who are registered at
their place of origin rather than where they have moved in
search of work, and who make up more than 10% of the
Chinese population [70]. Response rates among individu-
als invited for physical examination and blood sampling
were high, demonstrating that the traditional reluctance
of Chinese individuals to provide blood samples can be
overcome. As anticipated, the response rate among those
invited to undergo endoscopy was lower, and led to some
response bias, but the number of participants undergoing
endoscopy was still substantial (n = 1030).
The reliability and validity of the survey instruments in
the current study were demonstrated for the modified
Rome II questionnaire and ESS, and confirmed for the SF-
36 and RDQ. Each questionnaire had a high Cronbach's
alpha coefficient (≥ 0.8), suggesting good reliability. The
internal consistency of the RDQ dimensions replicated
findings from the original RDQ, as well as other language
Table 6: Correlation between Reflux Disease Questionnaire (RDQ) item score and dimension scores (correlation coefficients ≥ 0.6 are 
in bold).
RDQ item Spearman correlation coefficient
Regurgitation dimension Heartburn dimension GERD dimension Dyspepsia dimension
Burning behind breastbone
Frequency 0.37 0.84 0.67 0.42
Severity 0.37 0.84 0.66 0.42
Pain behind breastbone
Frequency 0.31 0.85 0.63 0.40
Severity 0.32 0.86 0.64 0.41
Acid taste
Frequency 0.85 0.34 0.77 0.40
Severity 0.87 0.32 0.77 0.40
Movement of materials
Frequency 0.80 0.34 0.72 0.38
Severity 0.81 0.33 0.73 0.38
Epigastric burning
Frequency 0.42 0.46 0.52 0.78
Severity 0.40 0.44 0.50 0.78
Epigastric pain
Frequency 0.36 0.37 0.44 0.86
Severity 0.37 0.34 0.42 0.85
GERD, gastroesophageal reflux disease.BMC Gastroenterology 2009, 9:86 http://www.biomedcentral.com/1471-230X/9/86
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versions [48,71]. Although test-retest reliability, known-
groups validity and responsiveness to change were not
assessed, the test-retest reliability of the Chinese versions
of the RDQ and SF-36 was previously established in the
Shanghai pilot study [27]. The construct validity of the
questionnaires was also credible. As found in the Shang-
hai pilot study and previous studies in China, the social
functioning dimension of the SF-36 tends to perform less
well than other dimensions [27,54], and vitality is more
strongly associated with mental health among Chinese-
speaking people [54,72-75]. It seems likely that these var-
iations reflect underlying cultural perceptions and social
standards regarding the relationship between health,
energy (or 'qi') and social functioning in China [54]. This
limits the reliability of conclusions reached on the basis of
data from this SF-36 dimension in China, and highlights
the importance of assessing the psychometric validity of
survey instruments in different cultures and settings.
Conclusion
In summary, the methodology used to conduct this large,
multicentre epidemiological study of gastrointestinal dis-
eases in five regions across China was valid and credible,
and the survey questionnaires demonstrated acceptable
psychometric properties. The prevalence of gastrointesti-
nal diseases in these diverse regions of China, together
with any associations of symptoms with demographic
characteristics, health-related quality of life, sleep distur-
bance, and endoscopic, biopsy and laboratory findings,
will be described in subsequent publications. The SILC
study has the potential to make a major contribution to
the epidemiological understanding of symptoms of gas-
trointestinal diseases in China, and to provide insight into
the relationship between gastrointestinal symptoms and
endoscopic findings that is likely to be of global signifi-
cance.
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